Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03286530
Recruitment Status : Recruiting
First Posted : September 18, 2017
Last Update Posted : September 7, 2020
Washington University School of Medicine
Vanderbilt University
Ohio State University
Information provided by (Responsible Party):
Gabriela Hobbs, Massachusetts General Hospital

Brief Summary:

This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is:

• Ruxolitinib

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Acute Myeloid Leukemia in Remission Allogeneic Stem Cell Transplantation Drug: Ruxolitinib Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved ruxolitinib for this specific disease but it has been approved for other blood diseases.

In this research study, investigators are trying to discover if ruxolitinib will decrease chances of relapse after having an allogeneic stem cell transplantation.

Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. Many cancers have over active "cell signaling." What this means is that certain functions in the cancer cells never turn off and this makes them grow in an uncontrolled way. Ruxolitinib, shuts down the pathway that depends on the JAK2 tyrosine kinases. The JAK2 pathway is over active with acute myeloid leukemia. Ruxolitinib has also been shown to lower the rates of graft versus host disease, a complication of transplant. The exact way ruxolitinib does this is not yet clear but it may have to do with its ability to block the JAK2 pathway since this pathway can also lead to inflammation in the body.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)
Actual Study Start Date : November 3, 2017
Estimated Primary Completion Date : September 1, 2022
Estimated Study Completion Date : September 1, 2024

Arm Intervention/treatment
Experimental: Ruxolitinib
Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
Drug: Ruxolitinib

Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.

After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment.

Other Name: Jakafi

Primary Outcome Measures :
  1. 1-year GVHD/relapse free survival rate (GRFS rate) [ Time Frame: 1 Year ]
    The number of participants surviving after one year that have not experienced graft-versus-host disease (GVHD) or graft relapse (GRFS rate).

Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Until disease progression or death from any cause, approximately 5 years ]
    Kaplan-Meier estimates of progression free survival (PFS) will be calculated, with patients without an event being censored at last date of contact

  2. Overall Survival [ Time Frame: Until death, approximately 5 years ]
    Overall survival is measured as the time from the hematopoietic stem cell transplantation (HSCT) until death. Participants without an event will be censored at the date of last contact.

  3. Cumulative incidence of drug related toxicities [ Time Frame: 2 Years ]
    Cumulative incidence of treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE 4). Early deaths from all other causes are considered a competing risk.

  4. Time to Relapse [ Time Frame: 2 Years ]
    The amount of time from the hematopoietic stem cell transplantation (HSCT) until disease relapse. Relapse is the recurrence of cancer after having a bone marrow biopsy without evidence of cancer. Time to treatment-related mortality is considered a competing risk.

  5. Time to treatment-related mortality (TRM) [ Time Frame: 2 Years ]
    The amount of time between receiving the HSCT and death due to a treatment related cause. Time to relapse is considered a competing risk.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must have pathologically confirmed AML in CR1 as defined by:

    • Bone marrow biopsy with < 5% blasts
    • No clusters or collections of blast cells
    • No extramedullary leukemia
    • Absolute neutrophil count ≥ 1000/µL (achieved post-induction at some point)
    • Please note that full platelet recovery is not necessary, and thus, patients achieving CRp are eligible.
  • Participants must be designated to undergo reduced intensity allogeneic peripheral blood hematopoietic stem cell transplantation (HCT). Consent will be obtained prior to admission for HCT. The following HCT conditions must be planned:

    • Donors must be 8/8 HLA-matched (at the allele level) as defined by matching at HLA-A, -B, -DR and -C who pass institutional standard to serve as a peripheral blood stem cell donor
    • Donor grafts must be G-CSF mobilized peripheral blood stem cells with dose and apheresis logistics at the discretion of institutional standard
    • Conditioning therapy will be one of the following 3 options:

      • Fludarabine / Melphalan where fludarabine is ≥ 90 mg/m2 IV total dose and melphalan is 100-140 mg/m2 IV total dose. Exact logistics of administration are at the discretion of institutional standard.
      • Fludarabine / Busulfan where fludarabine is ≥ 90 mg/m2 IV total dose and busulfan = 6.4 mg/kg IV total dose. Exact logistics of administration are at the discretion of institutional standard.
      • Fludarabine / Busulfan where fludarabine is ≥ 90 mg/m2 IV total dose and busulfan is dosed to achieve AUC of 4000 µmol/min based on a pharmacokinetics determined from a test dose. Exact logistics are at the discretion of institutional standard.
      • GVHD prophylaxis is comprised of tacrolimus / short course methotrexate as defined by tacrolimus started prior to day 0 of HCT and methotrexate given after HCT on days +1, +3 and +6 ± +11 at a dose of 5-10 mg/m2 IV. Exact logistics are at the discretion of the treating institution.
  • Age ≥ 60 and ≤ 80 years old
  • ECOG performance status 0-2
  • Male participants must agree to use an acceptable method for contraception during the entire study treatment period and through 6 months after the last dose of treatment.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Have had a prior allogeneic HSCT.
  • Patients without normal organ function defined as follows:

    • Platelet count of ≤50,000/ μL, hemoglobin of ≤8g/dL, or ANC of ≤1000 AST (SGOT), ALT (SGPT) and Alkaline Phosphatase ≥5 × institutional Upper Limit of Normal (ULN)
    • Direct bilirubin >2.0 mg/dL
    • Adequate renal function as defined by calculated creatinine clearance ≤ 40 mL/min (Cockcroft-Gault formula)
  • Have a history of other malignancy(ies) unless:

    • They have been disease-free for at least 5 years and are deemed by the treating investigator to be at low risk for recurrence of that malignancy,

      --- or

    • The only cancer they have had is cervical cancer in situ, or basal cell or squamous cell carcinoma of the skin
  • Have a chronic or active infection that requires systemic antibiotics, antifungal or antiviral treatment.
  • Have current or a history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF < 40%, as measured by MUGA scan or echocardiogram)
  • Have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Be HIV-positive and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with ruxolitinib. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy.
  • Have a systemic infection requiring IV antibiotic therapy, nor any other severe infection
  • Planned use of ex vivo or in vivo T-cell depletion
  • Have current or a history of ventricular or life-threatening arrhythmias or diagnosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03286530

Layout table for location contacts
Contact: Gabriella Hobbs, MD 617-726-8747

Layout table for location information
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02115
Contact: Myrna Nahas, MD    617-667-9920      
Principal Investigator: Myrna Nahas, MD         
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Gabriella Hobbs, MD    617-726-8748      
Principal Investigator: Gabriella Hobbs, MD         
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63130
Contact: Mark Schroeder, MD   
Principal Investigator: Mark Schroeder, MD         
United States, Ohio
The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Sumithira Vasu, MBBS   
Principal Investigator: Sumithira Vasu, MBBS         
United States, Tennessee
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37235
Contact: Michael Byrne, MD   
Principal Investigator: Michael Byrne, MD         
United States, Wisconsin
Medical College of Wisconsin Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Sameem Abedin, MD   
Principal Investigator: Sameem Abedin, MD         
Sponsors and Collaborators
Massachusetts General Hospital
Washington University School of Medicine
Vanderbilt University
Ohio State University
Layout table for investigator information
Principal Investigator: Gabriell Hobbs, MD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: Gabriela Hobbs, Prinicipal Investigator, Massachusetts General Hospital Identifier: NCT03286530    
Other Study ID Numbers: 17-273
First Posted: September 18, 2017    Key Record Dates
Last Update Posted: September 7, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gabriela Hobbs, Massachusetts General Hospital:
Acute Myeloid Leukemia
Acute Myeloid Leukemia in Remission
Allogenic Stem Cell Transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type